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ORIGINAL ARTICLE
Background/Aims: Acidic saline injections produce mechanical hyperresponsiveness in male Sprague-Dawley
rats. We investigated the effect of milnacipran in conjunction with tramadol on the pain threshold in an acidic
saline animal model of pain.
Methods: The left gastrocnemius muscle of 20 male rats was injected with 100 µL of saline at pH 4.0 under brief
isoflurane anesthesia on days 0 and 5. Rats administered acidic saline injections were separated into four study
subgroups. After determining the pre-drug pain threshold, rats were injected intraperitoneally with one of the following
regimens; saline, milnacipran alone (60 mg/kg), milnacipran (40 mg/kg) plus tramadol (20 mg/kg), or milnacipran (40
mg/kg) plus tramadol (40 mg/kg). Paw withdrawal in response to pressure was measured at 30 min, 120 min, and 5
days after injection. Nociceptive thresholds, expressed in grams, were measured with a Dynamic Plantar
Aesthesiometer (Ugo Basile, Italy) by applying increasing pressure to the right or left hind paw until the rat withdrew
the paw. 
Results: A potent antihyperalgesic effect was observed when tramadol and milnacipran were used in
combination (injected paw, p=0.001; contralateral paw, p=0.012). This finding was observed only at 30 min after
the combination treatment. 
Conclusions: We observed potentiation of the antihyperalgesic effect when milnacipran and tramadol were
administered in combination in an animal model of fibromyalgia. Further research is required to determine the
efficacy of various combination treatments in fibromyalgia in humans. (Korean J Intern Med 2009;24:139-142)
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INTRODUCTION
The acidic saline animal model of pain is thought to
mimic human chronic pain syndromes such as fibromyal-
gia (FM). In this model, repeated intramuscular (IM)
injections of acidic saline produce widespread hyperalge-
sia that persists without evidence of significant peripheral
tissue damage or inflammation, and is believed to be cen-
trally maintained [1]. IM acid injections alter the basal
pattern of brain activation in rats [2]. The overwhelming
reduction of regional cerebral blood flow (rCBF) in
multiple brain structures following acid injections is
consistent with reports of decreased rCBF in unstimulated
patients with FM [3,4]. 
Milnacipran is a dual norepinephrine and serotonin
reuptake inhibitor approved for the treatment of depre-
ssion in Europe and Asia, but it is currently unavailable in
the US [5]. The results of a 12-week, randomized, placebo-
controlled, dose-finding trial for milnacipran have been
reported; 25-200 mg/day of milnacipran or placebo was
given as a daily or twice-daily regimen during the first 4
weeks followed by 8 weeks at a stable dose [6]. Most FM
patients titrated to the highest dose of 200 mg/day whether
they were dosed once or twice daily. A significantly higher
percentage of patients receiving milnacipran twice daily
(37%) than placebo (14%) reported a reduction in weeklyaverage pain scores. 
Data from imaging studies are beginning to explain
clinical observations that opioid analgesics may be less
effective or require higher dosing in patients with FM
because of the reduced availability of opioid binding sites
[7]. Many studies have shown that compounds known to
block monoamine uptake, such as tricyclic antidepressants,
potentiate the antinociceptive effects of opioids [8,9].
Tramadol proved useful in patients with FM in a rando-
mized, placebo-controlled study [10]. 
Data regarding the efficacy of pharmacologic com-
bination treatment for FM are very limited. To our know-
ledge, no study has examined pharmacologic combination
treatment in an acidic saline pain model. To provide a
basis for pharmacologic combination treatment for
human FM, we studied the efficacy of milnacipran in
conjunction with tramadol for hyperalgesia in an acidic
saline animal model of pain. 
METHODS
All experiments were approved by the Animal Care and
Use Committee at Dongguk University and were in
accordance with the guidelines of the International
Association for the Study of Pain.
Twenty male Sprague-Dawley rats weighing 250-320 g
were used in these experiments. The rats were maintained
on a 12-h dark/light cycle with ad libitum access to
standard rat chow and water, and then brought to the
behavioral testing room an hour before testing for
acclimatization. Behavioral tests were usually performed
between 10:00 and 15:00. The left gastrocnemius muscle
was injected with 100 µL of saline at pH 4.0 under brief
isoflurane (2%) anesthesia on days 0 and 5.
Rats with acidic saline injection were separated into
four study subgroups according to intraperitoneal injection
regimen (group 1: milnacipran 60 mg/kg alone, group 2:
milnacipran 40 mg/kg + tramadol 20 mg/kg, group 3:
milnacipran 40 mg/kg + tramadol 40 mg/kg, group 4:
saline). After measurement of the control pre-drug pain
thresholds, rats were injected intraperitoneally with
either of the following regimens; saline, milnacipran 60
mg/kg alone, and milnacipran 40 mg/kg in combination
with tramadol 20 or 40 mg/kg. When milnacipran and
tramadol were administered in combination, each agent
was injected to the different regions of abdomen to prevent
any possible incompatibility. Paw withdrawal thresholds
to paw pressure were again measured 30 min, 120 min,
and 5 days after injection. Milnacipran was a generous
gift of Bukwang Pharma (Republic of Korea). Tramadol
was also a generous gift of Janssen Korea Ltd. (Republic of
Korea).
Ipsilateral and contralateral paw withdrawal responses
were measured in response to mechanical stimuli on days
0 (baseline), 7, and 12. The tests were performed by an
experimenter blinded to the treatment groups. Nociceptive
thresholds, expressed in grams (g), were measured using a
Dynamic Plantar Aesthesiometer (Ugo Basile, Italy) by
applying increasing pressure to the right or left hind paw
until the rat withdrew the paw. A maximal cut-off value of
50 g was used to prevent tissue damage.
The threshold was tested five times for each time point
and the mean values were used in the analysis. One-way
analysis of variance (ANOVA) followed by post hoc analysis
for multiple comparisons were used to evaluate the
differences between groups for each time point.
RESULTS
Compared to baseline (day 0), acid injections produced
mechanical hyper-responsiveness on day 7 (pre-drug
administration, p<0.05, Fig. 1 and 2). However, when
milnacipran and tramadol were administered in combi-
nation via intraperitoneal injection, a potent antihy-
peralgesic effect was observed in the injected paw
(p=0.001, Fig. 1). A similar antihyperalgesic effect was
also observed in the contralateral paw when the two drugs
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Figure 1. Effect of the combined use of tramadol and milnacipran
on the pain threshold in the acid injected paw of the rats (n=20). A
potent antihyperalgesic effect was observed when the two drugs
were used in combination This was only observed at 30 min of the
combination treatment. Milnacipran and tramadol were
administered simultaneously to the different regions of abdomen.
PD, pre-drug; gp, group; min, minutes; hrs, hours. *p=0.001
P
a
w
 
w
i
t
h
d
r
a
w
a
l
 
f
o
r
c
e
 
(
g
)
Day 0 Day 7
(PD)
Day 7
(30 min)
Day 7
(2 hrs)
Day 12
45
40
35
30
25
20
15
10
5
0
*
gp1: milnacipran 60 mg/kg
gp2: milnacipran 40 mg/kg
+ tramadol 20 mg/kg
gp3: milnacipran 40 mg/kg
+ tramadol 40 mg/kg
gp4: salinewere used in combination (p=0.012, Fig. 2). However,
these antihyperalgesic effects were observed only at 30
min after the combination treatments. 
An additional increase in the pain threshold of the
contralateral paw was observed at 30 min after treatment
when 40 mg/kg of tramadol was combined with mil-
nacipran 40 mg/kg (Fig. 2). However, this increase was
not statistically significant. 
DISCUSSION
In the present study, unilateral IM injections of acidic
saline produced bilateral mechanical hyperresponsiveness
in Sprague-Dawley rats. In this model, a potent antihyper-
algesic effect was observed when milnacipran (40 mg/kg)
was combined with tramadol at a dose of 20 or 40 mg/kg.
An increase in the pain threshold was observed not only in
the paws on the injected side, but also in paws on the non-
injected side of rats with hyperalgesia. 
The affinity of antidepressants for opioid receptors is
low [11]; therefore agonist-like effects of antidepressants
on opioid receptors are unlikely [12]. Apart from a direct
mechanism by which opioid receptors may be engaged by
milnacipran, an indirect pathway may be involved in the
observed increase in pain threshold in this study, perhaps
via inhibition of the release of endogenous opioid peptides
[13]. Several animal studies showed an increase in central
nervous system (CNS) opioid peptide levels or immuno-
reactivity after antidepressant treatment [14,15]. However,
the mechanism by which antidepressants may increase
the release of opioid peptides is yet to be identified. The
results of previous studies, as well as those of the present
study, indicate that further investigation is necessary to
obtain more detailed information regarding the interaction
of milnacipran and other non-tricyclic antidepressants
with opioidergic receptors.
Although there is no established experimental animal
model for FM, the acidic saline animal model of pain has
been suggested to mimic FM [1]. Hyperalgesia is thought
to result from changes occurring in multiple regions of
the CNS, a massive integrated neural network [16,17].
Thus, the pain modulation system of the CNS should be
investigated more widely. Although electrophysiological
techniques are useful to investigate the pain modulation
system, the identification of molecules that function in
the system remains difficult. Kim et al. [18] reported that,
compared to control animals, acid-injected rats showed
increased expression of several pain-associated molecules
in specific structures of the CNS. In addition, unilateral IM
injections of acidic saline altered the basal pattern of
activation in multiple CNS structures [2]. These data
support the validity of the acidic saline assay as a model
of FM, and provide a foundation for future analyses of
the contribution of specific brain structures and cellular
mechanisms to the development and maintenance of
central pain syndromes.
Pregabalin has been shown to be efficacious in other
pain conditions, including postoperative pain and FM.
Specifically, in people with FM, pregabalin (450 mg/day)
reduced pain, improved sleep, and increased quality of life
[19]. More recently, it was reported that pregabalin
reduced muscle and cutaneous hyperalgesia in an acidic
saline model of rats [20]. Data regarding the effect of
pharmacologic combination treatment in patients with
FM are limited, and no study regarding pharmacologic
combination treatment in an acidic saline model has been
published to date. In this study, we demonstrate that a
combined treatment regimen consisting of milnacipran
and reduced-dosage tramadol provides adequate additive
or supra-additive therapeutic effects with minimal adverse
effects. Efforts to define optimal drug combinations for
the relief of FM are continuing, and studies of other drugs
in combination with antidepressants are potentially
valuable. Therefore, further research is required to
determine the efficacy of these combinations in patients
with FM.
In conclusion, we demonstrated that the antihyperalgesic
effect of milnacipran was potentiated when administered
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Figure 2. Effect of the combined use of tramadol and milnacipran
on the pain threshold in the contralateral paw of the rats (n=20). A
potent antihyperalgesic effect was observed when the two drugs
were used in combination. This was only observed at 30 min of the
combination treatment. Milnacipran and tramadol were
administered simultaneously to the different regions of abdomen.
PD, pre-drug; gp, group; min, minutes; hrs, hours. *p=0.012
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*in combination with tramadol in an animal model of FM.
Further research is required to determine the efficacy of
various combination treatments in FM in humans.
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